Indivior PLC
04 September 2018

Indivior's CEO to Participate in Morgan Stanley's 16th Annual Global Healthcare Conference on September 13th

Slough, UK and Richmond, VA, September 4, 2018 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will discuss Indivior's progress at Morgan Stanley’s 16th Annual Global Healthcare Conference on September 13th, 2018, at 11:10 a.m. local time, in New York City. Mark Crossley, CFO, and Jason Thompson, VP of Investor Relations, will also participate. Thaxter’s remarks will be webcast live and the broadcast will be available on the “Investors” section of Indivior’s website (www.indivior.com) under “Upcoming Events.” If you plan on listening to the live webcast please allow sufficient time to register and download any audio software required to access the discussion.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20‐year legacy of leadership in patient advocacy and health policy while providing education on evidence‐based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co‐occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 1000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson
Vice President, Investor Relations
Tel: 804‐423‐8916 or jason.thompson@indivior.com

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCFKDDNNBKDNFN